Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vect-Horus, a biotechnology company that develops peptide and pseudo-peptide-based vector molecules for drug targeting and delivery to the central nervous system (CNS), has filed a new patent for vector VH0445.
Subscribe to our email newsletter
Vect-Horus has revealed the publication of its first patent in the ‘Institut National de la Propriété Intellectuelle’ (INPI) on April 23, 2010 (publication number FR2937322). The patent aims at protecting the first family of vectors of the company.
Vect-Horus has also reported the publication of the worldwide extension (PCT) of this patent (publication number WO2010/046588) by the European Patent Office on April 29, 2010. Finally, Vect-Horus has filed with the INPI a new patent to strengthen its intellectual property.
Vect-Horus said that under the leadership of Michel Khrestchatisky, scientific counselor and co-founder of Vect-Horus and Patrick Vlieghe, head of development and in charge of the chemical optimisation of vectors, VH0445, the lead vector of it has demonstrated its relevance by improving very significantly the delivery of a therapeutic agent into the brain compared to the same agent administrated without vector. Proof of efficacy of the vector was obtained on treatment of acute pain in an animal model.
Vect-Horus claimed that to deliver drugs into the CNS, it has developed a technology platform used in the discovery and development of peptide vectors that bind to specific receptors of the BBB, known to promote the transport of natural molecules across the BBB. Each receptor is thus used by Vect-Horus as a ‘Trojan horse’ for the transport across the BBB of vector-drug conjugates.
VH0445 recent analogs covered by the new patent are obtained by medicinal chemistry-based optimisation. The patent filed with the INPI describes new peptide analogs of VH0445 with potential for the development of new vectors with improved properties. When combined with various drugs, these vectors should improve the effectiveness of drugs in the treatment of several major diseases of the CNS.
Alexandre Tokay, CEO and co-founder of Vect-Horus, said: “Our IP portfolio protects our first family of vectors. Analogs of VH0445 that we have just patented are very promising and thanks to the implementation of our technology platform, we are very confident in our ability to discover and develop other families of vectors to facilitate the treatment of neurological disorders and major brain diseases.”